{"url_path":"/sec/fate/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-220696-index.html","accession_number":"0001193125-26-220696","cik":"0001434316","ticker":"FATE","issuer_name":"FATE THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-220696-index.html","primary_entity_key":"0001434316","primary_entity_name":"FATE THERAPEUTICS INC"},"word_count":600,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nExhibit\n\nNumber\n\n \n\nExhibit Title\n\n \n\nForm\n\n \n\nFile No.\n\n \n\nExhibit\n\n \n\nFiling Date\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1434316/000119312513351036/d590580dex32.htm)\n\n \n\nS-1/A\n\n \n\n333-190608\n\n \n\n3.2\n\n \n\nAugust 29, 2013\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.2\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect](https://www.sec.gov/Archives/edgar/data/1434316/000119312521184402/d191657dex31.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n3.1\n\n \n\nJune 7, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.3\n\n \n\n[Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock](https://www.sec.gov/Archives/edgar/data/1434316/000119312516778378/d301639dex31.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n3.1\n\n \n\nNovember 29, 2016\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.4\n\n \n\n[Amended and Restated Bylaws of the Registrant, as currently in effect](https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex33_493.htm)\n\n \n\n10-K\n\n \n\n001-36076\n\n \n\n3.3\n\n \n\nFebruary 24, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.5\n\n \n\n[Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Class A Convertible Preferred Stock of Fate Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1434316/000095017023013471/fate-ex3_1.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n3.1\n\n \n\nApril 19, 2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.6\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect](https://www.sec.gov/Archives/edgar/data/1434316/000119312524158374/d764437dex31.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n3.1\n\n \n\nJune 10, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.7\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect](https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374dex31.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n3.1\n\n \n\nMay 30, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.1\n\n \n\n[Specimen Common Stock Certificate](https://www.sec.gov/Archives/edgar/data/1434316/000119312513351036/d590580dex41.htm)\n\n \n\nS-1/A\n\n \n\n333-190608\n\n \n\n4.1\n\n \n\nAugust 29, 2013\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.2\n\n \n\n[Form of Pre-Funded Warrant](https://www.sec.gov/Archives/edgar/data/1434316/000119312521005180/d95890dex41.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n4.1\n\n \n\nJanuary 8, 2021\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.3\n\n \n\n[Form of Pre-Funded Warrant](https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/d799248dex41.htm)\n\n \n\n8-K\n\n \n\n001-36076\n\n \n\n4.1\n\n \n\nMarch 21, 2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.4\n\n \n\n[Description of Securities](https://www.sec.gov/Archives/edgar/data/1434316/000119312526073699/fate-ex4_4.htm)\n\n \n\n10-K\n\n \n\n001-36076\n\n \n\n4.4\n\n \n\nFebruary 26, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.1#\n\n \n\n[Amended and Restated Non-Employee Director Compensation Policy, effective March 31, 2026](fate-ex10_1.htm)\n\n \n\n—\n\n \n\n \n\n—\n\n \n\n \n\n—\n\n \n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1\n\n \n\n[Certification of Principal Executive Officer pursuant to Rules 13a-14 and 15-d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](fate-ex31_1.htm)\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2\n\n \n\n[Certification of Principal Financial Officer pursuant to Rules 13a-14 and 15-d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](fate-ex31_2.htm)\n\n \n\n—\n\n \n\n \n\n—\n\n \n\n \n\n—\n\n \n\n \n\nFiled herewith\n\n84\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1*\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](fate-ex32_1.htm)\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).\n\n \n\n—\n\n \n\n—\n\n \n\n—\n\n \n\nFiled herewith\n\n# Indicates a management contract or any compensatory plan, contract or arrangement.\n\n* This exhibit is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n85\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nFate Therapeutics, Inc.\n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Bahram Valamehr\n\nBahram Valamehr, Ph.D., MBA\n\nPresident, Chief Executive Officer and Director\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Kamal Adawi\n\nKamal Adawi, M.S., MBA\n\nChief Financial Officer and Treasurer\n\n(Principal Financial and Accounting Officer)\n\n \n\n86"}